Members |
targetComponentId |
Three female babies |
Number of female fetuses |
Three hundred and sixty degree translocation of macula |
Translocation of retina (procedure) |
Three male babies |
Number of male fetuses |
Three male babies |
Number of male fetuses |
Three previous induced terminations of pregnancy |
Past pregnancy history of multiple induced termination of pregnancy |
Throat anti-infective preparation |
Product manufactured as oromucosal dose form (product) |
Throat preparation |
Product manufactured as oromucosal dose form (product) |
Thrombocytopenia NOS |
Thrombocytopenic disorder |
Thrombocytopenia NOS |
Thrombocytopenic disorder |
Thrombocytopenia: [congenital purpura] or [hereditary NEC] |
Hereditary thrombocytopenic disorder (disorder) |
Thrombolytic agent |
Thrombolytic agent (substance) |
Thrombophilia due to acquired protein C deficiency |
Acquired protein C deficiency (disorder) |
Thrombophilia due to acquired protein S deficiency |
Acquired protein S deficiency |
Thrombosis of renal vein |
Thrombosis of renal vein |
Thrombosis of vein NOS |
Venous thrombosis |
Thrombosis of vein NOS |
Venous thrombosis |
Thrombotic microangiopathy NOS |
Thrombotic microangiopathy (disorder) |
Thrombus due to any device, implant AND/OR graft |
Thrombosis (disorder) |
Thumb X-ray |
Plain X-ray of thumb (procedure) |
Thumb X-ray |
Plain X-ray of thumb (procedure) |
Thumb X-ray |
Plain X-ray of thumb (procedure) |
Thumb pulp flap |
Flap (substance) |
Thymoma - category |
Thymoma |
Thymoma, no International Classification of Diseases for Oncology subtype |
Thymoma of uncertain behaviour |
Thymoma, type A |
Thymoma, type A, malignant |
Thymoma, type AB |
Thymoma, type AB, malignant |
Thymoma, type B1 |
Thymoma, type B1, malignant |
Thymoma, type B2 |
Thymoma, type B2, malignant |
Thymoma, type B3 |
Thymoma, type B3, malignant |
Thymosin alpha 1 1.6mg powder for conventional release solution for injection vial |
Product containing only thymalfasin (medicinal product) |
Thymosin alpha 1 1.6mg powder for injection solution vial + diluent |
Product containing only thymalfasin (medicinal product) |
Thymoxamine 0.5% conventional release eye drops |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
Thymoxamine 0.5% preservative-free eye drops |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
Thyroid TNM finding |
American Joint Committee on Cancer allowable value |
Thyroid disease monitoring NOS |
Thyroid disease monitoring |
Thyroid disease monitoring NOS |
Thyroid disease monitoring |
Thyroid eye disease with exophthalmos |
Exophthalmos due to thyroid eye disease (disorder) |
Thyroid eye disease with strabismus |
Exophthalmos due to thyroid eye disease (disorder) |
Thyroid gland excision |
Thyroidectomy |
Thyroid incision NOS |
Incision of thyroid |
Thyroid incision NOS |
Incision of thyroid |
Thyroid related antibody |
Thyroid antibody |
Thyroiditis NOS |
Thyroiditis |
Thyroiditis NOS |
Thyroiditis |
Thyrotoxicosis NOS |
Thyrotoxicosis |
Thyrotoxicosis NOS |
Thyrotoxicosis |
Thyrotropin alfa 0.9mg/mL powder for injection solution vial |
Thyrotrophin only product |
Thyrotropin alfa 1.1mg/vial powder |
Thyrotrophin only product |
Thyroxine sodium 100micrograms tablet |
Levothyroxine sodium anhydrous 100 microgram oral tablet |
Thyroxine sodium 25micrograms tablet |
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug) |
Thyroxine sodium 50micrograms tablet |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
Tibia X-ray |
Plain X-ray of tibia |
Tic disorder unspecified |
Tic (finding) |
Tic disorder unspecified |
Tic (finding) |
Ticarcillin 3g/clavulanic acid 100mg powder for injection solution vial |
Product containing precisely clavulanic acid (as clavulanate potassium) 100 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Ticarcillin disodium 1g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Ticarcillin disodium 20g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 20 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Ticarcillin disodium 3g powder for injection solution vial |
Product containing precisely ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Tiludronate disodium |
Product containing tiludronic acid (medicinal product) |
Time since symptom started NOS |
Symptom findings in relation to start time |
Time since symptom started NOS |
Symptom findings in relation to start time |
Time symptom lasts NOS |
Symptom findings in relation to time lasts (finding) |
Time symptom lasts NOS |
Time symptom lasts |
Time zone syndrome |
Jet lag (finding) |
Timed unsupported steady stand test |
Timed unsupported steady stand time |
Timolol maleate 0.25% ophthalmic solution |
Timolol (as timolol maleate) 2.5 mg/mL eye drops |
Timolol maleate 0.5% |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
Timolol maleate 0.5% ophthalmic solution |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
Timolol maleate+bendroflumethiazide |
Product containing bendroflumethiazide and timolol (medicinal product) |
Tinnitus symptom NOS |
Tinnitus |
Tinnitus symptom NOS |
Tinnitus |
Tiotropium 18microgram inhalation powder capsule |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
Tiotropium 18microgram inhalation powder capsule with device |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
Tis (0): Carcinoma in situ (limited to fallopian tube mucosa) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis (0): Carcinoma in situ (vagina) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis category |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Carcinoma in situ ("flat tumor" of urinary bladder) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Carcinoma in situ (endometrium/uterine cervix) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Carcinoma in situ |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Epithelium only (carcinoma in situ, no invasion) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Intratubular germ cell neoplasia (carcinoma in situ, testis) |
American Joint Committee on Cancer cTis (qualifier value) |
Tis: Tumor invades lamina propria (gastrointestinal tumor) |
American Joint Committee on Cancer cTis(LAMN) (qualifier value) |
Tis: Tumor invades muscularis mucosae (colon/rectum) |
American Joint Committee on Cancer cTis (qualifier value) |
Tissue culture for chromosome analysis, more complex procedure with special extra counts |
Chromosome analysis |
Tissue cytology NOS |
Cytologic test |
Tissue cytology NOS |
Cytologic test |
Tissue disruption operation NOS |
Tissue disruption operation |
Tissue disruption operation NOS |
Tissue disruption operation |
Tissue injection for local action |
Injection |
Tissue injection for local action NOS |
Injection |
Tissue injection for local action NOS |
Injection |
Tissue kallikrein |
Kininogen |
Tissue processing technique, complex, embed, cut and stain, per autopsy |
Tissue processing technique |
Tissue processing technique, complex, embed, cut and stain, per surgical specimen |
Tissue processing technique |
Titanium dioxide 20% paste |
Product containing only titanium dioxide (medicinal product) |
Tobacco consumption NOS |
Tobacco use and exposure |
Tobacco consumption NOS |
Tobacco use and exposure |
Tobacco dependence with current use |
Tobacco dependence syndrome |
Tobacco processor NOS |
Tobacco processor |
Tobacco processor NOS |
Tobacco processor |
Tobramycin 0.3%/fluorometholone 0.1% ophthalmic suspension |
Product containing precisely fluorometholone acetate 1 milligram/1 milliliter and tobramycin 3 milligram/1 milliliter conventional release eye suspension (clinical drug) |